Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,714 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Muscle Disorders Clear all

Conditions: Spinal Cord Injuries
Interventions: Acoustic stimuli (Startle); Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Nadofaragene Firadenovec, Durvalumab, Gemcitabine, Cisplatin, Radical Cystectomy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
Interventions: CHPP of Cisplatin, Abdominal Surgery; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 3 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec, Plasmapheresis; Genetic · Procedure
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 8 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Gainesville, Florida • St Louis, Missouri • Columbus, Ohio

Conditions: Intermittent Claudication
Interventions: Walking Exercise, Control--Resistance Training; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 35 Years to 100 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Facio-Scapulo-Humeral Dystrophy
Interventions: Not listed
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 13 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Muscular Dystrophies, Muscular Dystrophy, Duchenne
Interventions: delpacibart zotadirsen; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 2 Years and older · Male only
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 18 more

Conditions: Fatigue
Interventions: Exercise; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Fatigue Syndrome, Chronic Fatigue, Fibromyalgia
Interventions: Amygdala Retraining Program; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 59 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Inclusion Body Myositis
Interventions: ABC008; Drug
Lead sponsor: Abcuro, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 34
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 27 more

Conditions: Healthy, Neuromuscular Disease, Postpoliomyelitis Syndrome
Interventions: Electromyography; Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Movement Disorders, Parkinson's Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COPD, Obesity & Overweight, Sarcopenia
Interventions: Tirzepatide; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: PolG, Primary Mitochondrial Myopathy
Interventions: Not listed
Lead sponsor: The POLG Foundation; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: San Diego, California • Aurora, Colorado • New York, New York + 4 more

Conditions: Myotonic Dystrophy 1
Interventions: PGN-EDODM1 for infusion, Placebo; Drug · Other
Lead sponsor: PepGen Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Irvine, California • Palo Alto, California • Atlanta, Georgia + 4 more

Conditions: Spinal Cord Injuries, Tendinopathy, Rotator Cuff Tears, Shoulder Pain
Interventions: Lipogems, Dexamethasone; Device · Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Tethered Spinal Cord, Brain Tumor, Cranio Cervical Compression
Interventions: Isoflurane, Propofol, Dexmedetomidine; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 2 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Obesity, Overweight
Interventions: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 25
States / cities: Yuma, Arizona • Lake Forest, California • Long Beach, California + 22 more

Conditions: Bladder Cancer
Interventions: BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • New Brunswick, New Jersey

Conditions: Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophy
Interventions: Mobile neural decoding platform (mobile iBCI); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Acute Compartment Syndrome
Interventions: Near infrared spectroscopy (NIRS); Device
Lead sponsor: J&M Shuler; Industry
Eligibility: 15 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Syndromes, Plasma Cell Myeloma, Colon Carcinoma, Adenocarcinoma of Rectum, Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma
Interventions: Natural Killer (NK) Cells, ALT803; Biological
Lead sponsor: Brenda Cooper, MD; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heavy Menstrual Bleeding, Fibroid Uterus
Interventions: Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product; Other · Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Spinal Cord Injury, Muscle Spasticity
Interventions: Fampridine-SR, Placebo; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 27
States / cities: Birmingham, Alabama • Long Beach, California • Sacramento, California + 23 more

Search by objective public record fields.

Spasticity After Spinal Cord Injury

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Home-based vs. Supervised Exercise for People With Claudication

FSHD Molecular Characterization

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

Exercise for Prostate Cancer Patients

A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Electromyography to Diagnose Neuromuscular Disorders

A Study of Movement Disorders Using the QMAT At-Home Testing Device

GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

Prospective Natural History Study of POLG Disease

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury

Dexmedetomidine on Intraoperative Somatosensory and Motor Evoked Potential Monitoring During Neurosurgery in Pediatric Patients

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

iBCI Optimization for Veterans With Paralysis

The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury